Question

Which of the following best describes the molecular profile of Luminal B type breast carcinoma?

• A. ER+, PR+, Her2+
• B. ER+, PR-, Her2+
• C. ER-, PR+, Her2+
• D. ER-, PR-, Her-

Hint:

Luminal B breast cancers generally carry a worse prognosis than Luminal A tumors due to their higher cellular proliferation rates (high Ki-67) and/or HER2 gene amplification, often necessitating more aggressive chemotherapy alongside targeted anti-HER2 treatments.

Answer 1

The Correct Option is A

Concept:
The question tests the clinician's knowledge of the St. Gallen intrinsic molecular subtypes of breast cancer, specifically asking for the receptor expression profile that most accurately aligns with the Luminal B subtype based on the provided options.
The classification relies on the status of Estrogen Receptors (ER), Progesterone Receptors (PR), Human Epidermal Growth Factor Receptor 2 (HER2), and the Ki-67 cellular proliferation index.
Explanation:
• Breast cancer is no longer considered a single disease but is classified into distinct molecular subtypes that heavily dictate clinical prognosis and specific therapeutic strategies (endocrine therapy, targeted therapy, or chemotherapy).

• Luminal A: These tumors are typically strongly ER positive, PR positive (often with high expression), HER2 negative, and importantly, have a low proliferation index (Ki-67 generally $< 14-20\%$). They are the most common, slow-growing, and carry the best overall prognosis, responding excellently to endocrine therapy.

• Luminal B: This subtype is clinically more aggressive and proliferative than Luminal A. By definition, they are ER positive. However, they differ from Luminal A in that they may have significantly lower PR expression, a high proliferation index (Ki-67 $> 20\%$), OR they can be HER2 positive. When a tumor is ER+, PR+, and HER2+, it is often referred to clinically as "Triple Positive" and falls strictly into the Luminal B (HER2-amplified) category.

• HER2-enriched: These tumors are typically hormone receptor negative (ER negative, PR negative) but strongly HER2 positive.

• Basal-like (Triple Negative): These tumors are ER negative, PR negative, and HER2 negative.

• Analyzing the options: Option A represents a "triple-positive" tumor, which is the classic representation of a Luminal B (HER2-positive) breast cancer.

• Option D represents Triple Negative Breast Cancer. Options B and C are less standard profiles, but A perfectly encapsulates a major subclass of Luminal B disease.
Final Answer:
The molecular profile that best describes a Luminal B subtype among the given choices is ER+, PR+, Her2+.